α
AlphaScala
StocksSignalsNEWAlpha ScoreBriefingsNEWBrokers
Sign InGet Started
α
AlphaScala

Professional trading analysis with publicly tracked portfolios on TipRanks. Real trades, real data.

Markets

ForexStocksCryptoCommodities

Tools

Stock ResearchMarket SignalsMarket BriefingsAlpha ScoreHedge Funds 13FInsider BuysPolitician TradesAgentic TradingAI Broker MatcherBroker ReviewsPortfoliosFree IndicatorsBlogLearn TradingTrading Q&A

Account

Sign InDashboardNewsletterContact UsAdvertise

Legal

AboutMethodologyEditorial PolicyCorrectionsTerms of ServicePrivacy PolicyRisk Disclaimer

Risk Warning: AlphaScala provides educational content only and is not a financial advisor. Trading and investing involves substantial risk of loss and is not suitable for all investors. Past performance does not guarantee future results. You should consult a licensed financial advisor before making investment decisions. See our full risk disclaimer.

© 2026 ROGA AI LIMITED · Registered in Gibraltar · Unit G02, Eurocity, Europort Avenue, Gibraltar GX11 1AAAlphaScala – Built with data, not hype.
All Stocks/Healthcare/SVRA

Savara Inc

SVRA
HealthcareBiotechnology Website
Signal SnapshotMarket signals →
Alpha Score
Score pending
Alpha Score appears once the required price and fundamentals data has ingested.
Daily model
Insiders
No recent signal
No recent open-market insider buying or selling is in the current rollup.
Form 4
13F Holder
Marshall Wace
$27.50M reported position; latest action: new.
Institutional holder
Latest Filing
No filing digest
Recent 10-K, 10-Q, and 8-K summaries will appear here when available.
SEC digest
Price ChartPowered by TradingView
Ask about SVRAAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Marshall Wace4.56M$27.50MNEW
D.E. Shaw
David Shaw
1.67M$10.07MNEW
Citadel
Ken Griffin
804K$4.85MNEW
Renaissance Technologies
Jim Simons (founder)
332K$2.00MNEW
Explore all tracked funds →
About Savara Inc

Savara Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare and chronic respiratory diseases. Dedicated to addressing unmet medical needs, Savara Inc. aims to bring innovative treatment options to patients with limited therapeutic choices. One of their primary developments includes inhalation therapies that cater to conditions such as pulmonary alveolar proteinosis, cystic fibrosis, and other lung-related diseases. By investing in targeted therapies, Savara Inc. plays a crucial role in the healthcare and biotechnology sectors, emphasizing its commitment to improving patient outcomes with specific attention to safety and efficacy. Operating within the niche of rare diseases, Savara Inc. holds a unique position in the biopharmaceutical market, contributing to advancements in respiratory health care. The company's strategies and research efforts are pivotal in driving forward the development of new treatment modalities for critical respiratory conditions, thereby marking its significance in both the medical community and the pharmaceutical industry.

CEO
Mr. Matthew Pauls J.D., M.B.A.
Employees
70
Quick Facts
Exchange–
SectorHealthcare
IndustryBiotechnology
Market Cap–
Popular Stocks
AAPL
Apple Inc.
MSFT
Microsoft Corporation
NVDA
NVIDIA Corporation
AMZN
Amazon.com Inc.
GOOGL
Alphabet Inc. Class A
GOOG
Alphabet Inc. Class C
META
Meta Platforms Inc.
TSLA
Tesla Inc.
Key Dates

Earnings calendar coming soon. Subscribe to get notified when SVRA reports next.

Get earnings alerts →